Bliss GVS Pharma Ltd
Bliss GVS Pharma Ltd (BLISSGVS) last traded at ₹562, a market capitalisation of ₹5,967 crore, on a P/E of 43.4. Over the past 52 weeks the stock has ranged between ₹118 and ₹602. Bliss GVS Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹286 crore and net profit of ₹51 crore. The next scheduled event is an other on 19 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Bliss GVS Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Bliss GVS Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹286 cr, up 38.2% from ₹207 cr a year earlier. Net profit was ₹51 cr, up 15.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 218 | 210 | 198 | 207 | 244 | 218 | 257 | 286 |
| Expenses | 176 | 181 | 177 | 166 | 201 | 183 | 213 | 209 |
| Operating profit | 41 | 30 | 21 | 41 | 43 | 35 | 44 | 76 |
| OPM % | 19% | 14% | 11% | 20% | 18% | 16% | 17% | 27% |
| Other income | 5 | 15 | 12 | 35 | 8 | 16 | 11 | 10 |
| Interest | 4 | 1 | 2 | 5 | 3 | 1 | 2 | 1 |
| Depreciation | 7 | 8 | 8 | 8 | 8 | 8 | 9 | 10 |
| Profit before tax | 36 | 36 | 23 | 63 | 41 | 41 | 45 | 75 |
| Tax % | 28% | 29% | 29% | 30% | 30% | 39% | 18% | 32% |
| Net profit | 26 | 26 | 17 | 44 | 29 | 25 | 37 | 51 |
| EPS (₹) | 2.31 | 2.26 | 1.47 | 4.08 | 2.58 | 2.20 | 3.36 | 4.72 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Bliss GVS Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 577 | 747 | 752 | 770 | 810 | 927 | 1,005 |
| Operating profit | 107 | 118 | 117 | 151 | 127 | 168 | 199 |
| OPM % | 18% | 16% | 16% | 20% | 16% | 18% | 20% |
| Net profit | 74 | 23 | 77 | 82 | 90 | 135 | 142 |
| EPS (₹) | 6.64 | 1.45 | 6.80 | 7.21 | 8.00 | 12.21 | 12.86 |
TTM is the trailing twelve months to the most recent quarter.
Bliss GVS Pharma Ltd growth and returns
- 10 Years
- 5%
- 5 Years
- 10%
- 3 Years
- 7%
- TTM
- 21%
- 10 Years
- 5%
- 5 Years
- 14%
- 3 Years
- 23%
- TTM
- 29%
- 10 Years
- 15%
- 5 Years
- 40%
- 3 Years
- 80%
- 1 Year
- 245%
- 10 Years
- 11%
- 5 Years
- 9%
- 3 Years
- 10%
- Last Year
- 12%
Bliss GVS Pharma Ltd shareholding pattern
Promoters held 35.01% at Jun 2026, broadly unchanged since Jun 2025. FIIs 8.07% and DIIs 9.46%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 34.82% | 35.10% | 35.29% | 35.44% | 35.39% | 35.36% | 35.36% | 35.01% |
| FIIs | 12.13% | 13.51% | 13.18% | 12.65% | 13.27% | 14.54% | 10.45% | 8.07% |
| DIIs | 6.56% | 6.55% | 6.55% | 6.54% | 5.98% | 5.78% | 5.04% | 9.46% |
| Public | 46.49% | 44.84% | 44.98% | 45.37% | 45.36% | 44.32% | 49.15% | 47.45% |
| No. of shareholders | 52,937 | 49,558 | 49,517 | 46,707 | 44,461 | 43,380 | 44,874 | 46,767 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Bliss GVS Pharma Ltd events
The next scheduled event is an other on 19 Sept 2026.
- OtherPostal ballot for the appointment of Mr. Santosh Parab as a Non-Executive Non-Independent Director
- EGMAppointment of Mr. Santosh Parab as a Non-Executive and Non-Independent Director
See the full results calendar for every Indian company reporting in the next 30 days.
Bliss GVS Pharma Ltd corporate filings
- Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Bliss GVS Pharma has published a newspaper notice regarding the extension of the special…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: Bliss GVS Pharma Ltd has completed the mandatory regulatory requirement of publishing a…
Read the full analysis - Shareholder Meeting / Postal Ballot-Notice of Postal BallotAGM/EGMlow impact
Cruxal's analysis: Bliss GVS Pharma Limited has issued a notice of postal ballot to seek shareholder…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatehigh impact
Cruxal's analysis: Bliss GVS Pharma Limited has announced its unaudited financial results for the quarter…
Read the full analysis - Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019Company Updatelow impact
Cruxal's analysis: The Nomination and Remuneration Committee of Bliss GVS Pharma Limited approved the grant…
Read the full analysis - We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026, through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM"), with ....Board Meetinghigh impact
Cruxal's analysis: Bliss GVS Pharma Limited reported its unaudited financial results for the quarter ended…
Read the full analysis - We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held today i.e. August 11, 2026 has approved the allotment of 31, 250 equity shares of the face ....Company Updatelow impact
Cruxal's analysis: Bliss GVS Pharma Ltd has approved the allotment of 31,250 equity shares with a face value…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of IndiaInsider Trading / SASTlow impact
Cruxal's analysis: Bliss GVS Pharma Ltd has received a disclosure under SEBI Regulation 29(2) indicating…
Read the full analysis - Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....Board Meetinglow impact
Cruxal's analysis: Bliss GVS Pharma Limited has formally intimated the stock exchanges regarding a Board of…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Bliss GVS Pharma Ltd
Cruxal reads every Bliss GVS Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.